Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effects,...

Full description

Bibliographic Details
Main Authors: Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
breast cancer
HER2 overexpression
cardiotoxicity
supervised exercise program
prevention
supportive care
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1000846/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1000846/full

Similar Items